Physician profile
Eric B Newton
NPI 1952430019
$15,752.56
in general payments reported to CMS, 2019-2025
34 companies · $2,777 in 2025
The $2,777 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,937 · 2020: $636 · 2021: $1,614 · 2022: $2,310 · 2023: $3,006 · 2024: $3,472 · 2025: $2,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,245 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,244.75 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,031.41 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,243.41 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,245.42 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,155.08 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $953.88 | 2019-2025 | |
| Gilead Sciences, INC. | $865.92 | 2019-2025 | |
| Celgene Corporation | $680.28 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $417.43 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $395.18 | 2021-2025 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $381.72 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $374.27 | 2021-2024 | Ocaliva |
| Allergan, INC. | $248.46 | 2019 | |
| Lilly USA, LLC | $238.84 | 2023-2024 | Omvoh |
| Boston Scientific Corporation | $201.06 | 2019-2024 | |
| Medtronic, INC. | $173.35 | 2024 | Gi Genius |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $163.08 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $162.16 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $157.98 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $157.79 | 2019-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $110.95 | 2021-2024 | Rebyota |
| Shire North American Group INC | $61.92 | 2019 | |
| Genzyme Corporation | $53.45 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $50.28 | 2024 | Iqirvo |
| Amgen INC. | $42.95 | 2022-2023 | Amjevita, Avsola |
| Merck Sharp & Dohme LLC | $39.18 | 2022-2023 | Zinplava, Dificid |
| Fresenius Kabi USA, LLC | $34.96 | 2025 | Adalimumab-Aacf |
| Celltrion USA INC. | $24.98 | 2025 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.87 | 2023 | Cyltezo |
| Alnylam Pharmaceuticals INC. | $22.25 | 2023 | Givlaari |
| Organon LLC | $16.20 | 2023 | Renflexis |
| Orphalan INC | $15.37 | 2024 | Cuvrior |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Newton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.